FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     MAIER PAUL V						2. Issuer Name and Ticker or Trading Symbol International Stem Cell CORP [ ISCO.OB ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) (First) (Middle) C/O INTERNATIONAL STEM CELL CORP.			` ,			3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023								X		(give title		10% O Other (s below)	pecify	
9745 BUSINESSPARK AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	60 CA		92131											X		iled by One iled by More n	•	•		
(City) (State) (Zip)				1	Rule 10b5-1(c) Transaction Indication															
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						Execution Date,			Transaction Dispos Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 an				es For ally (D) following (I) (I		Direct	7. Nature of Indirect Beneficial Ownership		
									Code V		Amount	t (A) or (D) Price		e	Reporte Transact (Instr. 3	ection(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A Deemed Execution D if any (Month/Day/	c	ransaction		Derivative		6. Date Exercisab Expiration Date (Month/Day/Year)			7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		,   o   D   S		9. Number of derivative Securities Beneficially Owned Following Reported	, G F D 0 (1	0. Ownership form: Direct (D) r Indirect ) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				С	ode \	v	(A)	(D)	Date Exercisable	Ex <sub>i</sub>	piration te	Title	Amount or Number of Shares	er		Transaction (Instr. 4)	i(s)			
Stock Option (Right to Buy)	\$0.14	06/14/2023			A	30,000		(1)	06/	/14/2033	Common Stock	30,00	0	\$0.00	30,000		D			
Stock Option (Right to Buy)	\$0.14	06/14/2023			A		445,205		(2)	06/	/14/2033	Common Stock	445,2	05	\$0.00	445,205		D		

## Explanation of Responses:

- 1. Options vest fully at the earlier of (i) 06/14/2024 or (ii) the date of the 2024 Annual Meeting of Stockholders.
- 2. Options vest in four equal quarterly increments, beginning 09/14/2023.

/s/ Russell Kern, Attorney-in-<u>Fact</u>

06/16/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.